🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Tenax Therapeutics, Inc. TENX

Healthcare · Biotechnology · United States
https://www.tenaxthera.com
Company Profile ↓
$13.05
+109.81% 1Y
Mkt Cap$346.15M
P/E-8.82
P/B6.26
52W High$18.32
52W Low$5.85
Book Value$2.29
EPS (TTM)$-1.48

Company Overview

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Growth & Price Performance

Stock Price Performance

1 Year:+109.81%
6 Months:+0.77%
3 Months:+4.48%
1 Month:-24.91%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 58% of range
$5.85 $18.32
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)40.83 · Neutral
Price Performance
1M-24.91%
3M+4.48%
6M+0.77%
1Y+109.81%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 28.8% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-8.82
Industry PE
25.51
Forward P/E
-7.85
PEG Ratio
1.44
Book Value
$2.29
Price to Book
6.26
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-58.09%
ROE
-59.80%
ROA
-37.70%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.35
EPS (TTM)
$-1.48

Balance Sheet & Liquidity

Debt/Equity
0.52
Quick Ratio
14.61
Current Ratio
15.07
Debt
$0
Total Assets
$121.66M
Current Assets
$123.18M
Working Capital
$97.07M

Ownership

Promoter Holding
0.13%
Chg in Prom Hold
-
FII / Inst Holding
65.36%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$346.15M
Total Revenue (TTM)
$0
EBITDA
$-52.60M
Free Cash Flow
$-35.80M
Operating Cash Flow
$-35.80M
Shares Outstanding
26.53M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TENX Tenax Therapeutics, Inc. 13.05 -8.82 $346.15M 0.00% -58.09% -59.80% - -
2 UNH UnitedHealth Group Incorporated SPX 414.40 31.23 $376.34B 2.18% 9.74% 12.18% 10.40% 5.43%
3 WAT Waters Corporation SPX 400.00 50.96 $39.27B 0.00% 20.92% 5.21% 4.60% 2.80%
4 ZTS Zoetis Inc. SPX 74.39 12.20 $31.19B 2.74% 27.18% 67.75% 5.92% 18.61%
5 ZBH Zimmer Biomet Holdings, Inc. SPX 98.16 25.43 $18.99B 1.02% 6.61% 6.07% 4.50% -0.54%
6 BTSG BrightSpring Health Services, Inc. R2K 59.71 77.55 $11.72B 0.00% 6.47% 9.23% 18.69% -
7 NUVL Nuvalent, Inc. R2K 123.96 -20.46 $9.12B 0.00% -31.35% -41.19% - -
8 IBRX ImmunityBio, Inc. R2K 7.17 -8.44 $7.51B 0.00% -58.17% 70.21% 54.76% -
9 BLTE Belite Bio, Inc 158.50 -62.16 $6.35B 0.00% -10.07% -18.93% - -171.21%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jan 2015Mar 2015Jun 2015Jul 2015Sep 2015Oct 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----------------------------------00000-
Cost of Revenue ----------------------------------------
Gross Profit 0---------------------------------------
Operating Expenses ----------------------------------11.34M11.79M16.81M16.45M16.57M-
Operating Income -3.13M-3.20M-4.87M-3.11M-3.10M-3.75M-5.71M4.67M4.50M3.50M3.01M1.31M1.22M1.89M1.55M1.66M1.82M2.26M2.67M2.14M2.23M23.75M1.96M3.80M2.72M2.86M2.92M-1.54M1.24M2.12M-3.91M-3.67M-4.62M--11.34M-11.79M-16.81M-16.45M-16.57M-
EBITDA -----------------------------------11.34M-10.85M-15.80M-15.54M-16.57M-
Interest Expense ----------------------------------4650000--
Pretax Income -----------------------------------10.41M-10.85M-15.80M-15.54M-15.72M-
Tax Provision ----------------------------------------
Net Income -2.87M-2.94M-4.75M-3.03M-2.92M-3.52M-5.36M4.64M4.27M3.28M2.99M1.23M1.19M1.87M1.54M1.62M1.76M2.22M-2.65M-2.15M-2.22M-23.75M-1.72M3.80M-2.72M-2.86M2.92M-1.41M-1.11M1.97M-3.80M-3.58M-3.96M--10.41M-10.85M-15.80M-15.54M-15.72M-
Diluted EPS -0.10------------------------------3.12-1.83-0.19--0.28-0.27-0.40--0.35-0.35
R&D Expense 1.23M1.58M1.95M1.75M1.68M2.52M3.94M-3.43M-3.23M-2.05M-1.22M-253.97K-58.59K-311.15K-362.63K-482.77K-649.25K-916.98K-1.34M1.27M1.05M22.38M693.22K1.16M1.18M1.52M1.54M265.74K197.90K1.07M2.68M2.33M3.11M-5.68M6.12M10.33M-11.54M12.85M

Profit & Loss (Annual)

Figures in USD.

Metric Apr 2011Apr 2012Apr 2013Apr 2014Apr 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 103.17K363.78K1.19M158.93K49.29K0-----0000
Cost of Revenue ---------------
Gross Profit 103.17K49.27K49.57K-104.07K00---------
Operating Expenses -----------11.05M8.23M19.49M56.38M
Operating Income 10.56M-8.22M-5.19M-16.61M-14.82M-52.65M-9.21M-6.89M-8.56M9.87M--11.05M-8.23M-19.49M-56.38M
EBITDA ------------10.93M-7.68M-17.58M-52.60M
Interest Expense -----------4.44K24.00K23.00K0
Pretax Income ------------11.05M-7.71M-17.60M-52.60M
Tax Provision ---------------
Net Income 10.45M-15.71M-9.42M-19.54M-14.08M-43.92M-8.84M-14.14M-8.39M-9.85M--11.05M-7.71M-17.60M-52.60M
Diluted EPS -0.45-14.07-6.68-2.71--------600.71-31.04-1.15-1.34
R&D Expense 2.68M2.46M2.46M3.00M6.66M13.14M3.53M1.24M3.47M4.56M25.15M5.38M3.23M12.71M32.67M

Balance Sheet (Annual)

Figures in USD.

Metric May 1967Apr 2010Apr 2011Apr 2012Apr 2013Apr 2014Apr 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --2.92M4.14M3.18M93.43M82.91M72.99M23.34M9.89M13.34M6.37M6.87M-3.40M11.69M96.69M104.23M
Current Assets --------------3.21M11.68M96.69M104.23M
Cash & Equivalents 0632.71K951.94K1.88M783.53K58.32M7.93M3.66M10.00M1.60M12.37M4.91M6.25M-2.12M9.79M94.85M97.56M
Inventory ------------------
Receivables ------------------
Total Liabilities --6.65M4.49M4.96M10.54M12.48M12.56M6.20M1.01M1.57M2.59M2.24M-1.91M3.59M4.69M7.16M
Current Liabilities --2.18M3.13M1.91M2.57M4.52M4.60M6.20M1.01M1.57M2.53M2.12M-1.85M3.59M4.69M7.16M
Long Term Debt ------------------
Total Debt -------------290.78K807.89K501.00K--
Total Equity -2.13M-3.72M-346.05K-1.78M82.86M70.43M60.42M17.14M8.88M11.77M3.77M4.63M-1.49M8.10M91.99M97.07M
Shares Outstanding --------------28.65K298.28K3.42M9.31M

Cash Flows (Annual)

Figures in USD.

Metric Apr 2011Apr 2012Apr 2013Apr 2014Apr 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -8.40M-8.28M-4.92M-9.26M-9.75M-15.87M-12.14M-5.50M-7.56M-9.27M--11.39M-5.90M-14.81M-35.80M
Investing Cash Flow -463.94K-261.15K-147.99K-147.04K-40.93M22.21M3.75M7.35M-1.65K20.11K452.61K-2.32K3.00K0-
Financing Cash Flow 9.19M9.47M3.97M66.95M280.59K008.91M96.50K10.60M-7.93M13.57M99.87M38.51M
Capital Expenditure -240.82K-17.65K-17.20K-9.80K-4.23K-2.88K-4.54K-7.59K-3.57K-3.49K-5.25K-2.32K---
Free Cash Flow -8.64M-8.30M-4.94M-9.27M-9.75M-15.87M-12.15M-5.51M-7.56M-9.28M--11.39M-5.90M-14.81M-35.80M
Net Change in Cash ------------3.46M7.67M85.06M2.71M

Ratios (Annual)

Figures in %.

Metric Apr 2011Apr 2012Apr 2013Apr 2014Apr 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 100.0%13.5%4.2%-65.5%0.0%----------
Operating Margin % 10,238.4%-2,259.7%-435.7%-10,452.1%-30,062.8%----------
Net Margin % 10,127.6%-4,319.2%-790.6%-12,296.2%-28,571.6%----------
ROE % -280.5%4,540.6%529.6%-23.6%-20.0%-256.3%-99.5%-120.2%-222.5%-213.0%--740.1%-95.2%-19.1%-54.2%
ROCE % 1,429.1%-809.8%-408.2%-18.3%-18.9%-307.2%-103.6%-58.6%-223.2%207.8%--709.9%-101.7%-21.2%-58.1%

Shareholding Pattern

Insiders
0.13%
Institutions
65.36%
Public Float
65.44%

Top Institutional Holders

#Holder% HeldSharesValue
1 Price (T.Rowe) Associates Inc 11.13% 2.95M $42.29M
2 Janus Henderson Group PLC 6.84% 1.82M $26.02M
3 Venrock Adviser, LLC 6.32% 1.68M $24.01M
4 Perceptive Advisors Llc 5.46% 1.45M $20.75M
5 Ikarian Capital, LLC 3.84% 1.02M $14.58M
6 Stonepine Capital Management, LLC 3.68% 975.20K $13.97M
7 Logos Global Management LP 2.36% 625.00K $8.96M
8 Morgan Stanley 2.25% 596.56K $8.55M
9 Velan Capital Investment Management LP 2.20% 583.33K $8.36M
10 Adage Capital Partners GP L.L.C. 2.04% 540.13K $7.74M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TENX

Yahoo Finance Fri, 31 Jul 2026

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today re…

Yahoo Finance ue, 21 Jul 2026

Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know

The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimat…

Yahoo Finance hu, 02 Jul 2026

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel ca…

Yahoo Finance hu, 02 Jul 2026

Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June

US stocks look set to open higher in Thursday's trading session as investors parse key employment da

Yahoo Finance hu, 02 Jul 2026

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax…

Yahoo Finance ue, 12 May 2026

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of T…

TENX — Frequently Asked Questions

What is the current share price of Tenax Therapeutics, Inc. (TENX)?

As of 2026-08-05 17:25 PDT, Tenax Therapeutics, Inc. (TENX) trades at $13.05 on NasdaqCM. Its 52-week range is $5.85 to $18.32.

What is the market capitalisation of TENX?

Tenax Therapeutics, Inc. (TENX) has a market capitalisation of $346.15M on NasdaqCM.

What is the P/E ratio of TENX?

TENX trades at a trailing price-to-earnings (P/E) ratio of -8.82. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is 6.26.

What is the return on equity (ROE) of TENX?

TENX has a return on equity (ROE) of -59.80%. Its return on capital employed (ROCE) is -58.09%.

Is TENX a good stock to buy?

This page provides a data-driven analysis of Tenax Therapeutics, Inc. (TENX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space